DMRA
Research Snapshot
Static fundamentals, valuation context, and investor signals for DAMORA THERAPEUTICS, INC. (DMRA).
DCF ready
Valuation
N/A
EV/FCF, N/A FCF yield
Quality
-87.3%
ROIC, N/A FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 13.0x current ratio
Superinvestors
1
Top: Viking Global Investors (0.2%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
Watchouts
- Valuation multiples are limited or unavailable.
Annual data: 7 periods
Quarterly data: 24 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for DMRA.
Grade F
0
/ 100
Financial Charts
No financial data available for DMRA (annual).
1 superinvestors own DMRA
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Viking Global Investors Viking Global Investors | 2,311,082 | $60M | 0.17% | 0.0% |